Loading...
Loading chart...



The current price of SCPH is 0 USD — it has increased 0 % in the last trading day.
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company’s strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. Its commercial product, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Company’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Wall Street analysts forecast SCPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SCPH is11.84 USD with a low forecast of 5.35 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
scPharmaceuticals Inc revenue for the last quarter amounts to 16.04M USD, increased 99.17 % YoY.
scPharmaceuticals Inc. EPS for the last quarter amounts to -0.34 USD, decreased -22.73 % YoY.
scPharmaceuticals Inc (SCPH) has 162 emplpoyees as of February 09 2026.
Today SCPH has the market capitalization of 157.56M USD.